Drug
Daraxonrasib
Daraxonrasib: highest development phase Phase 3, developed by Revolution Medicines, United Therapeutics. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Revolution Medicines, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| daraxonrasib NCT07252232 | Phase 3 | Pancreatic Cancer |
| daraxonrasib NCT06881784 | Phase 3 | NSCLC (Non-small Cell Lung Cancer) |
| daraxonrasib NCT07805954 | Phase 3 | Pancreatic Cancer |
| daraxonrasib NCT07491445 | Phase 3 | Pancreatic Cancer |
| Daraxonrasib NCT07793253 | Phase 2 | Biliary Tract Cancers |
| Daraxonrasib NCT07397338 | Phase 1/2 | Advanced Solid Tumors |
| Daraxonrasib NCT07898813 | Phase 1 | Pancreatic Ductal Adenocarcinoma |
Latest
No recent events.
Follow Daraxonrasib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.